Atopic Dermatitis May Be Linked to Increased Risk for CKD
By Elana Gotkine HealthDay Reporter
TUESDAY, July 15, 2025 -- Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, according to a study published online July 10 in the Journal of Dermatology.
Hsi-Chih Chen, from the Tri-Service General Hospital at the National Defense Medical Center in Taipei, Taiwan, and colleagues conducted a nationwide, longitudinal study to examine the correlation between AD and the risk for CKD using data from Taiwan's National Health Insurance Research Database. A total of 15,179 individuals with AD were identified and compared to 60,716 age- and sex-matched individuals without AD.
The researchers found that after adjustment for potential confounders, patients with AD had an elevated risk for CKD compared with the non-AD comparison cohort (adjusted odds ratio, 1.30). In both men and women and in all age groups, the association between AD and an increased risk for CKD was evident. There was a trend toward increasing odds ratios seen with increasing frequency of clinical visits for AD.
"Our findings remained robust in subgroup analyses, which demonstrate that a positive association exists between AD and CKD risk in both genders and in all age groups," the authors write. "The clinical implications of the present study merit further investigation."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
AAP Updates Screening Guidance for Child Mental Health, Behavioral Problems
MONDAY, Aug. 25, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Aug. 25 in Pediatrics, updated recommendations are presented for...
Discordance Seen Between Care Goals, Treatment Intent in Advanced Cancer
MONDAY, Aug. 25, 2025 -- More patients with advanced cancer report that their treatment discordantly focuses on longevity over comfort than patients with other illnesses...
Apitegromab Improves Motor Function in Spinal Muscular Atrophy
MONDAY, Aug. 25, 2025 -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.